Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
Philippe Merle(Hôpital de la Croix-Rousse), Gabriele Luppi(University of Modena and Reggio Emilia), Jean Delwaide(Centre Hospitalier Régional et Universitaire de Nancy), Driffa Moussata(European CanCer Organisation), Michael Schultheiß(University of Freiburg), Julie Le Boulicaut, Thierry Fontanges, Ursula Ehmer(TUM Klinikum), Imam Waked(Menoufia University), Massimo Colombo(University of Milan), Faiza Khemissa-Akouz(Université Paris Cité), Hélène Regnault(Assistance Publique – Hôpitaux de Paris), Marc Peeters(University of Antwerp), Audrey Molé(Onxeo (France)), Aurore Baron, Sylvain Manfrédi, Alexander Zipprich(Jena University Hospital), Wolfgang Sieghart(Atitus Educação), Nelson S. Yee(Kettering University), Armand Abergel(Inserm), Georges‐Philippe Pageaux(Goethe University Frankfurt), B. Vasseur(Université de Montpellier), Isabelle Ollivier‐Hourmand(Inserm), Jean–Marc Phelip(Centre Hospitalier Universitaire de Saint-Étienne), P Attali(Hôpital Civil, Strasbourg), Albert Tran, Carine Richou(Centre Hospitalier Universitaire de Besançon), Éric Nguyen-Khac(Université de Lille), Vlad Ratziu(Inserm), A Maieron(Universitätsklinikum St. Pölten), Thomas Berg(Leipzig University of Applied Sciences), Jean‐Frédéric Blanc, Alice Gangloff(Centre Hospitalier Universitaire de Rouen), Mohamed Bouattour(Hôpital Beaujon), Yann Touchefeu(Canadian Partnership Against Cancer), René Gerolami(Méditerranée Infection Foundation), Amr S. Saad(Ain Shams University Hospital), Henning Wege(Universität Hamburg), Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Barbara Dauvois, Jean‐Pierre Zarski(Inserm), Marilyne Debette‐Gratien(Inserm), François Habersetzer(Inserm), Joerg Trojan, Jean–Pierre Bronowicki(Inserm), Julie Vincent(Inserm), Jean‐Didier Grangé, Luc Lasser, Gilles Pelletier(Hôpital Paul-Brousse), Ivan Borbath
Cited by 61
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k